Hexima Presenting at AusBiotech

Oct 26, 2021 | Webinars & Events

Mr Michael Aldridge, CEO of Hexima, presented today at AusBiotech’s “Australia Biotech Invest & Partnering Conference 2021”. AusBiotech is the leading Australian industry body representing and advocating for organisations doing business in and with the global life...

Review of FY21 – Investor Webinar

Sep 8, 2021 | Company News, Webinars & Events

Watch Hexima’s CEO, Mr Michael Aldridge, review the achievements of FY21 and inform investors of expected important developments and milestones. Hexima’s management appreciates the role that shareholders have played in the progress of the Company, and looks...

Consumer Centric Investor Webinar

Sep 2, 2021 | Webinars & Events

Watch Hexima CEO, Mr Michael Aldridge, and Hexima’s Commercial Consultant, Mr Phil Rose, discuss how Hexima is taking a consumer-centric view on product development to create a treatment that adequately meets the needs of patients. Hexima’s...

Presentation of Phase I/IIa study data at American Podiatric Medical Association (APMA) and Investor Webinar

Jul 29, 2021 | Webinars & Events

Joining the annual APMA 2021 Annual Scientific Meeting held from July 29 to August 1, was an important opportunity to share Hexima’s data on pezadeftide’s potential in the management of onychomycosis and discuss with leading physicians in this specialty. In the US,...

NailMail Q2 2021

Jul 28, 2021 | NailMail

Hexima Limited (ASX:HXL) is proud to release its “NailMail” quarterly activities report for the quarter ended 30 June 2021. Major achievements covered in this report: – Completing enrolment in phase IIb clinical trial for pezadeftide (formerly HXP124) as a...